Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases

Table 1

Baseline demographic and clinicopathologic characteristics of patients with metastatic liver-dominant NETs who received Y-90 radioembolization

Baseline characteristic	Number of patients (%)
Age at diagnosis of metastatic disease (years)
Median (range)	56.0 (20.71–78.14)
Gender
Male	24 (49%)
Female	25 (51%)
ECOG status at Y-90 treatment
0–1	46 (94%)
≥2	2 (4%)
Unknown	1
Location of primary NET
Pancreas	15 (31%)
Small bowel	20 (41%)
Large bowel	3 (6%)
Unknown	7 (14%)
Other	4 (8%)
Grade
1	30 (61%)
2	12 (25%)
3	1 (2%)
Unknown	6 (12%)
Ki-67 (%)
≤2	18 (37%)
3–20	17 (34%)
>20	1 (2%)
Unknown	13 (27%)
Mitotic count (/hpf)
<2	23 (47%)
2–20	13 (27%)
>20	0
Unknown	13 (27%)
Baseline chromogranin A
Median (range)	325 (7–44100)
Hepatic tumor burden
<33%	9 (18%)
33–66%	32 (65%)
>66%	7 (14%)
Unknown	1 (2%)
Number of extrahepatic metastases
0	34 (69%)
1	11 (22%)
2	3 (6%)
3	1 (2%)
Previous therapies
Surgical resection of primary tumor	31 (63%)
Local ablative therapy	12 (25%)
SSA	34 (69%)
Systemic therapy	17 (35%)
Dose of Y-90 (GBq)
Median (range)	2.2 (0.80–3.60)
Type of Y-90
TheraSpheres	14 (29%)
SIR-Spheres	34 (69%)
Unknown	1 (2%)
Type of treatment
Liver segment	43 (88%)
Whole liver	5 (10%)
Unknown	1 (2%)
Response to Y-90 radioembolization
Complete response	0
Partial response	26 (53%)
Stable disease	16 (33%)
Progressive disease	6 (12%)
Unknown	1 (2%)
Number of liver segments treated
1	9 (18%)
2	31 (63%)
3	4 (8%)
4	3 (6%)
Unknown	2 (4%)
Number of Y-90 treatments
1	34 (69%)
2	14 (29%)
3	1 (2%)